CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer

By sjmartinez • March 23, 2024

Lim RJ, Salehi-Rad R, Tran LM, Oh MS, Dumitras C, Crosson WP, Li R, Patel TS, Man S, Yean CE, Abascal J, Huang Z, Ong SL, Krysan K, Dubinett SM, Liu B. CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer. Cell Rep Med. 2024 Mar 19:101479. doi: 10.1016/j.xcrm.2024.101479. Epub ahead of print. PMID: 38518770.

Tags: Checkpoint blockade, CXCL10, CXCL9, CXCR3, dendritic cells, Fellow, Hematology/Oncology, immunosuppression, in situ vaccination, NSCLC, Publications, Pulmonary, Critical Care & Sleep Medicine, Resident, systemic immunity, T cells, Veterans Administration

Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study

McCann KE, Osman N, Cannon J, Brent L, Wang Y, Tepsick J, Mandora PV, Miller V, Martin N, Kaklamani VG. Goserelin 3-month depot shows non-inferiority[...]

A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative)

Rugo HS, Schmid P, Tolaney SM, Marmé F, Bardia A, Spears PA, Cortés J. A plain language summary of quality of life with sacituzumab govitecan[...]

Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates

Pala L, Merlo F, Sala I, Pagan E, Oriecuia C, Specchia C, Catania C, Cocorocchio E, Laszlo D, Ceresoli G, Locatelli M, De Pas T,[...]